Skip to main content

AlgoNomics and Pevion Biotech to Develop Peptides for Cold Vaccine

NEW YORK, Feb. 25 (GenomeWeb News) - AlgoNomics and Pevion Biotech will collaborate to develop peptides for cold vaccines, the companies said today.

 

Over a period of a year and a half, structural bioinformatics company AlgoNomics, based in Ghent, Belgium, will use its Tripole protein modeling and peptide design technologies to develop peptides derived from Respiratory Syncytial Virus, which causes the common cold and other respiratory illnesses.

 

Pevion, of Bern, Switzerland, plans to formulate the peptides using its virosome technology and to test vaccine candidates in clinical trials.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.